These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33599960)

  • 1. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
    Eichenfield LF; Siegfried E; Kwong P; McBride M; Rieger J; Glover D; Willson C; Davidson M; Burnett P; Olivadoti M
    Am J Clin Dermatol; 2021 Mar; 22(2):257-265. PubMed ID: 33599960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
    Eichenfield LF; McFalda W; Brabec B; Siegfried E; Kwong P; McBride M; Rieger J; Willson C; Davidson M; Burnett P
    JAMA Dermatol; 2020 Dec; 156(12):1315-1323. PubMed ID: 32965495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum.
    Niazi S; Brabec B; Anschutz L; Willson C; Davidson M; Burnett P
    J Drugs Dermatol; 2021 Jan; 20(1):70-75. PubMed ID: 33400412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region:
    Eichenfield LF; Kwong P; Gonzalez ME; Yan A; D'Arnaud P; Burnett P; Olivadoti M
    J Clin Aesthet Dermatol; 2021 Oct; 14(10):42-47. PubMed ID: 34976290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YCANTH
    Gupta AK; Mann A; Vincent K; Abramovits W
    Skinmed; 2023; 21(5):360-363. PubMed ID: 37945366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts.
    Guenthner S; McFalda W; Tate M; Eads K; Rieger J; Glover DK; Willson C; Rumney P; Rosen T; Andres J; Olivadoti M
    Am J Clin Dermatol; 2021 Nov; 22(6):867-875. PubMed ID: 34515985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review.
    Vakharia PP; Chopra R; Silverberg NB; Silverberg JI
    Am J Clin Dermatol; 2018 Dec; 19(6):791-803. PubMed ID: 30097988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cantharidin therapy for molluscum contagiosum in children.
    Epstein E
    J Am Acad Dermatol; 2001 Oct; 45(4):638. PubMed ID: 11568766
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial.
    Guzman AK; Schairer DO; Garelik JL; Cohen SR
    Int J Dermatol; 2018 Aug; 57(8):1001-1006. PubMed ID: 29904968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Molluscum contagiosum. Toxic shock syndrome following cantharidin treatment.
    Langley JM; Soder CM; Schlievert PM; Murray S
    Can Fam Physician; 2003 Jul; 49():887-9. PubMed ID: 12901485
    [No Abstract]   [Full Text] [Related]  

  • 11. Beetle juice: a guide for the use of cantharidin in the treatment of molluscum contagiosum.
    Moye V; Cathcart S; Burkhart CN; Morrell DS
    Dermatol Ther; 2013; 26(6):445-51. PubMed ID: 24552407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts.
    Guenthner S; McFalda W; Kwong P; Eads K; McCafferty M; Rieger J; Glover DK; Willson C; Burnett P; Olivadoti M
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1623-1634. PubMed ID: 34286459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: A randomized clinical trial.
    Hebert AA; Siegfried EC; Durham T; de León EN; Reams T; Messersmith E; Maeda-Chubachi T
    J Am Acad Dermatol; 2020 Apr; 82(4):887-894. PubMed ID: 31586600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molluscum Contagiosum: An Update.
    Leung AKC; Barankin B; Hon KLE
    Recent Pat Inflamm Allergy Drug Discov; 2017; 11(1):22-31. PubMed ID: 28521677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial.
    Browning JC; Enloe C; Cartwright M; Hebert A; Paller AS; Hebert D; Kowalewski EK; Maeda-Chubachi T
    JAMA Dermatol; 2022 Aug; 158(8):871-878. PubMed ID: 35830173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients.
    Silverberg NB; Sidbury R; Mancini AJ
    J Am Acad Dermatol; 2000 Sep; 43(3):503-7. PubMed ID: 10954663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of topical cantharidin and intralesional PPD to treat molluscum contagiosum.
    Khattab FM; Nasr MM
    J Dermatolog Treat; 2020 Dec; 31(8):850-854. PubMed ID: 31418621
    [No Abstract]   [Full Text] [Related]  

  • 18. Cantharidin Topical Solution 0.7%: First Approval.
    Keam SJ
    Paediatr Drugs; 2024 Jan; 26(1):95-100. PubMed ID: 38007409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis.
    Paller AS; Green LJ; Silverberg N; Stripling S; Cartwright M; Enloe C; Wells N; Kowalewski EK; Maeda-Chubachi T
    Pediatr Dermatol; 2024; 41(3):438-444. PubMed ID: 38413239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cantharidin for the treatment of molluscum contagiosum: a prospective, double-blinded, placebo-controlled trial.
    Coloe Dosal J; Stewart PW; Lin JA; Williams CS; Morrell DS
    Pediatr Dermatol; 2014; 31(4):440-9. PubMed ID: 22897595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.